Journal article
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Abstract
The inhaled corticosteroid fluticasone furoate (FF) and the long-acting β₂ agonist vilanterol (VI) are in development as a combined once-daily therapy for asthma and chronic obstructive pulmonary disease. Our study objectives were to compare the efficacy and safety of once-daily FF/VI with FF alone and twice-daily fluticasone propionate (FP) in patients aged ≥12 years with moderate-to-severe persistent asthma. Patients (n=586) received FF/VI …
Authors
O’Byrne PM; Bleecker ER; Bateman ED; Busse WW; Woodcock A; Forth R; Toler WT; Jacques L; Lötvall J
Journal
European Respiratory Journal, Vol. 43, No. 3, pp. 773–782
Publisher
European Respiratory Society (ERS)
Publication Date
March 2014
DOI
10.1183/09031936.00064513
ISSN
0903-1936
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAndrostadienesAnti-Asthmatic AgentsAsthmaBenzyl AlcoholsChlorobenzenesDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleForced Expiratory VolumeGlucocorticoidsHumansHydrocortisoneMaleMiddle AgedPulmonary Disease, Chronic ObstructiveQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesTreatment Outcome